Epithalon
Epitalon
Epithalon (Epitalon, and the related natural pineal extract Epithalamin) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG), promoted as an anti-aging, telomere-lengthening and pineal-regulating "geroprotector." There is a large gap between marketing and evidence: nearly all supportive human data come from a single Russian/Ukrainian research group (Khavinson/Anisimov/Korkushko) studying mostly the extract Epithalamin — not the synthetic peptide — in small, methodologically weak, unreplicated trials published in low-impact journals. For the synthetic peptide specifically, human evidence is essentially limited to one uncontrolled retinitis-pigmentosa report; the mechanistic claims (telomerase induction, telomere elongation) rest on in-vitro cell-culture work. There is no rigorous human safety or pharmacokinetic characterization, no independent replication of the longevity claims, and no FDA/EMA-approved product. The single most important theoretical danger is that a peptide marketed for its ability to reactivate telomerase and, per a 2025 independent study, activate alternative lengthening of telomeres (ALT) in cancer cell lines could plausibly promote growth of an existing occult malignancy — this has never been evaluated for safety in humans. Products sold as "Epitalon" are unregulated research chemicals of unverified identity and purity; European regulators have documented it circulating in illegal preparations. Anyone using it should do so only with clinician oversight and stop immediately for any concerning symptom.
Mechanism of action
Pharmacokinetics
Not formally characterized in humans. As a small unmodified tetrapeptide it is expected to undergo rapid enzymatic hydrolysis by plasma and tissue peptidases, implying a very short circulating half-life (on the order of minutes) — but no validated human pharmacokinetic data exist to confirm this.
Unknown in humans. Trial regimens used repeated short courses (e.g., daily injections over 10-day cycles repeated over months/years), which implies the researchers did not rely on prolonged single-dose activity; any durable effect is hypothesized to occur via downstream gene-expression changes rather than sustained peptide presence.
Reported research/clinical routes include subcutaneous and intramuscular injection (the extract Epithalamin and the peptide in trials) and intranasal administration (studied in rodents as a route bypassing the blood-brain barrier). Oral bioavailability is expected to be negligible due to gastrointestinal peptide digestion. No route has validated human PK data.
Presumed proteolytic degradation into constituent amino acids (alanine, glutamate, aspartate, glycine) by ubiquitous peptidases, with renal handling of fragments; not experimentally characterized in humans. This washout/monitoring information is provided for clinical safety context only, not to guide timing or evade any testing.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- In vitro (human fibroblast culture): induction of hTERT/telomerase activity and telomere elongation, with cells continuing to divide beyond their normal replicative limit — a cell-culture finding, not a demonstrated human clinical outcome.
- In small unreplicated human trials of the related pineal extract Epithalamin: modulation of the nocturnal melatonin circadian rhythm (increased melatonin in subjects with initially low pineal activity), reported improvements in some cardiovascular, lipid and carbohydrate-metabolism indices in elderly patients, and reduced all-cause/cardiovascular mortality over multi-year follow-up.
- One uncontrolled clinical report of the synthetic peptide Epitalon described improved retinal bioelectrical/functional activity in patients with retinitis pigmentosa.
- Preclinical (rodents/flies): reported lifespan extension, anticarcinogenic/antimetastatic effects in some models, and antioxidant effects.
- Marketed/anecdotal claims of anti-aging, improved sleep, and skin/wellbeing benefits are not supported by adequate controlled human data.
Adverse effects by system
No rigorous human safety data for the synthetic peptide. The single-group Epithalamin extract trials reported favorable cardiovascular changes (lower blood pressure, improved lipids) rather than harm, but these were small, unreplicated, and not adverse-event-focused; genuine cardiovascular safety of injected Epithalon in humans is unestablished.
No human hepatotoxicity data. No signal of liver injury has been reported, but liver enzymes and function were not systematically monitored in the available literature; hepatic safety is effectively unstudied.
No evidence that Epithalon suppresses the hypothalamic-pituitary-gonadal axis; it is not an androgen, anabolic steroid, or SERM. Its documented endocrine action is modulation of pineal melatonin secretion. Effects on reproductive/gonadal hormones in humans are unstudied. Any endocrine concern should be evaluated by an endocrinologist.
No adequate human data. Some rodent work reported restored reproductive function in old animals; relevance to humans is unknown and reproductive safety (including in pregnancy/lactation, where it must be avoided) is uncharacterized.
No controlled human psychiatric data. Because it may alter melatonin/circadian signaling, theoretical effects on sleep and mood are plausible but unquantified; no established psychiatric adverse-effect profile exists.
No human renal safety data. Cleared fragments are handled renally in principle, but nephrotoxicity has not been assessed; renal safety is unknown.
No human hematologic safety data; blood counts and coagulation parameters were not systematically studied. Hematologic effects are unknown.
No systematic human data. Injection-site reactions (pain, redness, swelling, infection risk) are a generic hazard of any injected unregulated peptide, but Epithalon-specific dermatologic effects are unreported.
HPTA suppression & recovery
Suppression: No evidence of HPTA suppression; not a SERM, androgen, or anabolic steroid
Epithalon is a pineal-derived tetrapeptide with no known mechanism of hypothalamic-pituitary-gonadal axis suppression, so SERM-based recovery frameworks (which are single-SERM only and outside this compound's relevance) do not apply. However, human reproductive-endocrine effects have not been studied. Anyone with concerns about gonadal or pituitary function while using this or any peptide should consult an endocrinologist for individualized assessment; do not self-manage hormonal issues.
Monitoring
Cadence: Establish a baseline before use; if used despite the weak evidence, re-check basic labs periodically (e.g., every few months) under clinician supervision, and pursue prompt targeted evaluation for any warning sign. There is no evidence-based monitoring schedule specific to this peptide because human safety studies do not exist.
- Any unexplained lump, mass, unusual bleeding, persistent lymph node enlargement, or unexplained weight loss (potential malignancy signal) — stop and seek medical evaluation immediately
- Injection-site infection: spreading redness, warmth, swelling, pus, or fever
- Systemic allergic/anaphylactic signs: rash, hives, facial/throat swelling, difficulty breathing — emergency care
- New chest pain, palpitations, severe headache, or syncope
- Significant new sleep disruption or mood change
- Jaundice, dark urine, right-upper-quadrant pain, or persistent nausea (possible hepatic issue)
Contraindications
- Active or suspected/occult malignancy, or significant personal/family cancer risk — a peptide marketed for telomerase reactivation, and shown in vitro to activate ALT in cancer cell lines (PMID 40908429), carries a theoretical risk of promoting existing tumor growth that has never been evaluated for human safety.
- Pregnancy and breastfeeding — no safety data.
- Children/adolescents — no data; developmental effects unknown.
- Known hypersensitivity to the peptide or excipients/diluents.
- Use of unregulated, non-pharmaceutical-grade product of unverified identity/purity (documented circulating in illegal preparations, PMID 25535022) — contamination and mislabeling are inherent hazards.
- Absence of clinician oversight / inability to obtain baseline and follow-up bloodwork.
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- The evidence base is weak and conflicted: nearly all supportive human data come from one research group, mostly on the extract Epithalamin rather than the synthetic peptide, are unreplicated, and were not designed to detect harm. Treat strong anti-aging claims as unproven.
- Do not use if you have, or are at elevated risk for, cancer. The telomerase-reactivating and ALT-activating properties raise a real theoretical risk of accelerating an existing occult tumor; this has never been tested for safety in humans. Get age-appropriate cancer screening before considering use.
- This is an unregulated research chemical. Products may be mislabeled, underdosed, contaminated, or non-sterile (Epitalon has been documented in illegal preparations). Injected non-sterile product risks abscess, bloodborne infection, and sepsis.
- Use only with a clinician's knowledge, with baseline bloodwork (CBC, liver and kidney function, lipids/glucose) and periodic follow-up. Never share needles; use sterile single-use injection technique.
- Stop immediately and seek medical care for: any new lump/mass, unexplained bleeding or weight loss, spreading injection-site redness or fever, signs of allergic reaction (swelling, trouble breathing), chest pain, jaundice, or persistent unusual symptoms.
- Avoid entirely in pregnancy, breastfeeding, and in minors. Do not combine with other unproven injectables to 'stack' effects.
- This monograph is harm-reduction information, not medical advice or an endorsement; discuss any use with a qualified clinician and defer hormonal/endocrine questions to an endocrinologist.
Citations (15)
Every clinical claim above is tied to a primary source. Overall evidence grade D — this compound lacks adequate human data; claims rest on preclinical or mechanistic evidence.
- 01
Epithalon is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), designed from the amino-acid composition of the pineal extract Epithalamin, and shares its proposed geroprotective actions.
ReviewPMID 12374906 ↗
- 02
In telomerase-negative human fetal fibroblast culture, Epithalon induced expression of the telomerase catalytic subunit, telomerase enzymatic activity, and telomere elongation (in-vitro mechanism).
PreclinicalDOI 10.1023/a:1025493705728 ↗
- 03
Epithalon treatment allowed human fetal fibroblasts to elongate telomeres and continue dividing past their normal replicative (Hayflick) limit in cell culture.
PreclinicalDOI 10.1023/b:bebm.0000038164.49947.8c ↗
- 04
An independent 2025 in-vitro study confirmed dose-dependent telomere elongation via hTERT/telomerase upregulation in normal human cells and telomere lengthening via ALT activation in cancer cell lines (basis for theoretical oncogenic concern).
PreclinicalDOI 10.1007/s10522-025-10315-x ↗
- 05
Multi-year randomized trials of the pineal EXTRACT Epithalamin in elderly people (single research group) reported reduced mortality and 'geroprotective' effects.
- 06
A 12-year randomized study of the extract epithalamine in elderly coronary patients reported decreased functional/cardiovascular aging and lower mortality (unreplicated, single group).
- 07
A 15-year follow-up randomized comparison reported that repeated epithalamin courses decelerated cardiovascular aging and normalized melatonin, lipid and carbohydrate metabolism in elderly coronary patients.
- 08
In elderly women with ischemic heart disease and hypertension, the extract Epithalamin reduced diurnal arterial pressure and improved lipid metabolism in a randomized study.
- 09
Epithalamin modulated the nocturnal melatonin circadian rhythm in elderly subjects, raising melatonin in those with initially low pineal activity.
- 10
Epithalamin was reported to reduce free-radical/lipid-peroxidation markers and increase antioxidant (SOD) activity in humans and animals (review of one group's data).
ReviewPMID 11335874 ↗
- 11
An uncontrolled clinical report of the synthetic peptide Epitalon described improved retinal function in patients with retinitis pigmentosa (no control group).
Case seriesPMID 12195242 ↗
- 12
Epitalon reduced spontaneous tumor development and metastases in mice (preclinical anticarcinogenic signal, not human safety data).
PreclinicalPMID 16634527 ↗
- 13
Epitalon inhibited chemically induced colon carcinogenesis in rats (preclinical).
PreclinicalDOI 10.1016/s0304-3835(02)00090-3 ↗
- 14
The pineal peptide preparation increased lifespan in fruit flies, mice and rats (preclinical longevity data, species other than human).
PreclinicalDOI 10.1016/s0047-6374(98)00034-7 ↗
- 15
Epitalon has been identified circulating in illegal/unregulated pharmaceutical preparations, underscoring product-identity and purity hazards.
Case reportDOI 10.1002/dta.1771 ↗
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice